Graviti Pharmaceuticals Initiates Class II Recall for Bupropion Hydrochloride ER 300mg Due to Failed Specifications
Graviti Pharmaceuticals Private Limited has initiated a Class II recall for 46,512 bottles of Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, due to failed tablet specifications. This impacts supply chains relying on the Hyderabad, India facility and its distributor, Rising Pharma Holdings, Inc. Procurement and regulatory teams must assess immediate supply risks and evaluate alternative generic Bupropion sources to mitigate disruption and ensure patient access.
Graviti Pharmaceuticals Initiates Class II Recall for Bupropion Hydrochloride ER 300mg
Graviti Pharmaceuticals Private Limited, based in Hyderabad, India, has initiated a voluntary Class II recall (D-0037-2026) for a significant quantity of Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg. This action, initiated on September 15, 2025, addresses a critical quality issue: the product failed tablet/capsule specifications. Specifically, 46,512 bottles of the 30-count presentation, identified by NDC 16571-863-03 and batch number BPB124341A with an October 2026 expiration date, are affected. For procurement directors, this means an immediate disruption to the supply of a widely used generic antidepressant and smoking cessation aid. The failure to meet tablet specifications can impact drug efficacy, dissolution rates, and potentially patient safety, necessitating prompt removal from the market. This recall underscores the persistent quality control challenges within certain overseas manufacturing facilities, directly affecting the reliability of the global pharmaceutical supply chain and requiring immediate attention to sourcing strategies.
Supply Chain Exposure: Impact on Distributors and Retailers
The recalled Bupropion Hydrochloride Extended-Release Tablets were distributed to a broad network within the United States, reaching one primary distributor and 16 wholesalers/pharmacy retailers nationwide. Rising Pharma Holdings, Inc. is identified as the distributor for this product, manufactured by Graviti Pharmaceuticals Private Limited. This extensive distribution pattern means that numerous downstream partners, including pharmacies and healthcare providers, are directly impacted by this Class II recall. For supply chain VPs and business development executives, this event highlights the cascading effects of a single manufacturing quality failure. Retailers and wholesalers must manage product returns, inventory adjustments, and potential stock-outs, leading to operational inefficiencies and financial losses. Furthermore, the recall of a product with application number ANDA211020, a generic version of a critical medication, creates immediate pressure to secure alternative supplies, potentially leading to price volatility and increased lead times for Bupropion Hydrochloride 300 mg. The commercial implications extend to reputational risk for both Graviti Pharmaceuticals and its distribution partners.
Facility Profile and Product Significance in the US Market
Graviti Pharmaceuticals Private Limited operates its manufacturing facility at E & 621 Patancheru Mandal, Isnapur Village Rd; Survey No 621, Sangareddy, Telangana, India, near Hyderabad. This facility is the source of the recalled Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg. Bupropion Hydrochloride is a widely prescribed medication for major depressive disorder and seasonal affective disorder, as well as for smoking cessation. Its extended-release formulation is crucial for patient compliance and consistent therapeutic effect. The failure of tablet specifications from an Indian manufacturing site underscores the ongoing scrutiny by the FDA on overseas pharmaceutical production quality. For regulatory affairs heads, this incident emphasizes the need for robust oversight of contract manufacturing organizations (CMOs) and their adherence to cGMP standards, particularly for complex formulations like extended-release products. Any lapse in quality at facilities like Graviti's can lead to significant market disruption and erode confidence in generic drug supplies originating from specific geographies, necessitating enhanced due diligence for future partnerships.
Navigating Supply Disruption: Alternative Sourcing Strategies for Bupropion
The recall of Graviti Pharmaceuticals' Bupropion Hydrochloride Extended-Release Tablets necessitates immediate action for procurement directors to identify and qualify alternative suppliers. While specific alternative manufacturers are not detailed in the available intelligence, the market for generic Bupropion Hydrochloride is competitive. Companies must prioritize suppliers with a strong track record of FDA compliance and robust quality systems. This involves rigorous due diligence, including facility audits, review of regulatory history, and assessment of product quality documentation. Geographic diversification of suppliers is a critical strategy to mitigate single-point-of-failure risks, especially from regions with a higher incidence of regulatory actions. Qualification timelines for new generic API or finished dosage form suppliers can range from 6 to 18 months, depending on the complexity of the product and the stringency of internal qualification processes. Therefore, proactive engagement with multiple pre-qualified manufacturers is essential to ensure continuity of supply for Bupropion Hydrochloride and similar critical medications, minimizing patient impact and market volatility.
Broader Regulatory Context and Compliance Risks in Generic Manufacturing
This Class II recall by Graviti Pharmaceuticals occurs within a broader landscape of heightened regulatory scrutiny on pharmaceutical manufacturing, particularly for generic drugs produced in India. While there is no specific prior regulatory history for Graviti Pharmaceuticals in the provided data, this event aligns with a trend of quality-related recalls. For instance, recent parallel events include Essential Wellness Pharma's Class II recall for Progesterone Injection due to sterility assurance failures, indicating a persistent focus by the FDA on fundamental quality attributes. Regulatory affairs heads must recognize that the FDA's enforcement posture remains stringent, with an emphasis on product specifications and manufacturing controls. A Class II classification, while not immediately life-threatening, signifies that the product could cause temporary or medically reversible adverse health consequences. This environment demands that companies sourcing from or manufacturing in regions like India implement enhanced quality management systems and conduct frequent internal and external audits to preempt such compliance risks and maintain market access.
Remediation Timeline and Future Outlook for Graviti Pharmaceuticals
As a voluntary, firm-initiated recall, Graviti Pharmaceuticals Private Limited is responsible for executing the recall process, investigating the root cause of the failed tablet specifications, and implementing corrective and preventive actions (CAPA). The recall status is currently 'Ongoing,' indicating that the process of retrieving affected product from the distribution chain is still active. For business development executives and regulatory affairs teams, Graviti's ability to swiftly and effectively remediate this issue will be critical. The FDA will expect a comprehensive response detailing the investigation, the scope of the problem, and the measures taken to prevent recurrence. Failure to adequately address the underlying quality issues could lead to further regulatory actions, including potential import alerts for products from their Hyderabad facility or a reclassification to a higher recall severity. Future partnerships and market access for Graviti Pharmaceuticals will hinge on demonstrating a robust commitment to quality and compliance, impacting their long-term commercial viability in the global generic drug market.